Deal of the Day — limited-time pharmacy picks!
Rolimus 5mg Tablet

Rolimus 5mg Tablet

Prescription requiredRx Required

Salt Composition: Everolimus

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

10 Tablet

About The Product

Kidney Cancer, Noncancerous tumors, Breast Cancer, Brain tumor, kidney tumor,Partial-onset seizures

null

Description

Rolimus 5mg tablet is a targeted therapy, immunosuppressant and and anticancer drug. The medicine is used in the treatment of kidney, breast, pancreatic and lung cancer. It also prevents organ rejection while transplanting any organ in the body. Its active ingredient is Everolimus which belongs to the group class of mTOR (mammalian target of rapamycin) inhibitors.

The medicine blocks the mTOR pathway, which controls cell growth, proliferation and blood vessels development thereby slowing the tumor growth. By inhibiting mTOR, it also reduces the activity of immune cells, preventing the body from rejecting targeted organs, helping to improve treatment outcomes and patient survival.


Uses

  • Treats kidney, breast, pancreatic and lung cancer. Also prevent organ rejection while transplanting body organs.

Side Effects

  • As with all medicines, Rituximab may affect people differently and some may experience side effects.
  • Most are temporary or mild, consult the healthcare professional if any of the symptoms persist or worsen: • Infection (chills, increased temperature) • Coughing • Wheezing • Excessive thirst • High urine output or severely decreased urine output • Tiredness • Bleeding • Increased appetite with weight loss • Difficulty breathing, or swallowing • Swelling of face, lips, tongue, throat • Severe itching, red rash, raised bumps​

How To Use

  • The dosage and number of infusions depend on the type of cancer or autoimmune condition being treated. The injection is usually given in hospital or clinics by a nurse or healthcare professional through intravenous infusion.
  • Treatment schedule can range from single infusion to multiple infusion over several weeks. Do not self administered, consult the doctor about correct dosage and duration before using Rolimus 5mg tablet.

How It Works

  • Rolimus 5mg tablet inhibits the mTOR pathway, which plays a key role in cell growth, division and blood formation. By blocking this pathway, it helps to control the growth of cancerous cells and reduces harmful immune activity in autoimmune conditions.
  • It also suppresses immune cell activity, helping to prevent organ rejection after transplantation, thereby improving treatment effectiveness and long term patient outcomes.

Safety Advice

Alcohol
Alcohol is strictly prohibited while using Rolimus 5mg tablet Consult the health care professional before using the medication.
Pregnancy
Pregnant women should avoid using Rolimus 5mg tablet as it harm the developing fetus in mother's womb. Consult the doctor for proper medical assistance.
Breast Feeding
Rolimus 5mg tablet has not been taken by breastfeed women as it passes from breast which harm the baby. For more information consult the doctor.
Driving
Rolimus 5mg tablet may cause dizziness, if you experience fainting and light headedness should avoid driving or operating machinery and sit and lie down until the feeling passes.
Kidney
Kidney patients should avoid using Rolimus 5mg tablet may affect the kidney function and making it hard to treat both the disease.
Liver
Rolimus 5mg tablet interrupt with the liver function. If you have pre-existing liver conditions or notice symptoms such as yellowing of skin or eyes (jaundice) should inform the doctor Immedietly. Regular monitoring should be required while taking this medication to ensure safety and effectiveness.

FAQs

• Follow the prescription as recommended by the healthcare professional • Monitor the side effects to ensure safety and effectiveness. • Swallow the whole tablet without chewing or crushing it.

• Avoid driving or dizziness while taking the medication​

References

• Houghton, P. J.

(2010). Everolimus.

Clinical cancer research, 16(5), 1368-1372. https://pubmed.ncbi.nlm.nih.gov/20179227/ • Hasskarl, J. (2018).

Everolimus. Small molecules in oncology, 101-123. https://link.springer.com/book/10.1007/978-3-319-91442-8 • Kirchner, G.

I., Meier-Wiedenbach, I., & Manns, M. P.

(2004). Clinical pharmacokinetics of everolimus.

Clinical pharmacokinetics, 43(2), 83-95. https://pubmed.ncbi.nlm.nih.gov/14748618/ • Chapman, T. M., & Perry, C.

M. (2004).

Everolimus. Drugs, 64(8), 861-872. https://pubmed.ncbi.nlm.nih.gov/15059040/ • Atkins, M.

B., Yasothan, U., & Kirkpatrick, P. (2009).

Everolimus. Nature reviews Drug discovery, 8(7), 535-536. https://pubmed.ncbi.nlm.nih.gov/19568281/​

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026